Results 71 to 80 of about 31,863 (238)

Challenges in prophylactic therapy with Emicizumab in patients with hemophilia A: Focus on monitoring tests

Romanian Journal of Laboratory Medicine
This study presents a transversal investigation that we performed at Fundeni hospital (Bucharest, Romania) into the therapeutic benefits and efficacy of Emicizumab, a non-factor therapy, in the context of hemophilia A.
Brinza Melen, Uscatescu Valentina, Hemcinschi Mihai, Chiriac Elisabeta, Gherghe Georgiana, Coriu Daniel   +5 more
doaj   +1 more source

Acquired hemophilia A

Hematology, 2006
Acquired hemophilia A is a rare but severe autoimmune bleeding disorder, resulting from the presence of autoantibodies directed against clotting factor VIII. The etiology of the disorder remains obscure, although approximately half of all cases are associated with other underlying conditions.
openaire   +2 more sources

Optimizing Emergency Department Care for People With Bleeding Disorders: A Scoping Review of Barriers and Interventions for Improvement

Haemophilia, EarlyView.
ABSTRACT Background Emergency department (ED) care is critical for managing acute bleeding events in people with bleeding disorders. Despite international guidelines recommending haemostatic treatment within 30–60 min, delays and deviations from best practices are common and associated with poorer outcomes.
Ling‐Yi Guo, Diane L. Lorenzetti, Natalia Rydz, Dawn Goodyear, Julia Hews‐Girard, Garrick Mok, Roy Khalife, Kelsey Uminski   +7 more
wiley   +1 more source

Real‐world use of emicizumab in Chinese children with hemophilia A: Retrospective data from a comprehensive care center

Pediatric Investigation
Importance Emicizumab (EMI) is efficacious and safe for hemophilia A (HA) prophylaxis. However, its high cost poses a challenge in China. Objective To explore the possibility of using reduced‐dosage EMI in Chinese HA children.
Qianqian Mao, Zhenping Chen, Guoqing Liu, Gang Li, Yingzi Zhen, Xiaoling Cheng, Zekun Li, Wanru Yao, Di Ai, Zhengping Li, Nan Wang, Man‐Chiu Poon, Runhui Wu   +12 more
doaj   +1 more source

Management of Breakthrough Bleeding During Emicizumab Prophylaxis in Acquired Haemophilia A: Data From the GTH‐AHA‐EMI Study

Haemophilia, EarlyView.
ABSTRACT Introduction The GTH‐AHA‐EMI study showed that emicizumab reduces bleeding in patients with acquired haemophilia A (AHA). However, 22 clinically relevant new bleeds (CRNB) occurred in 14 of the 47 study patients, most of which required haemostatic treatment.
Halet Türkantoz, Christiane Dobbelstein, Richard Greil, Christina Hart, Robert Klamroth, Paul Knöbl, Johannes Oldenburg, Christian Pfrepper, Ulrich Sachs, Inga M. Schimansky, Karolin Trautmann‐Grill, Andreas Tiede   +11 more
wiley   +1 more source

Use of an Oral Health‐Related Quality of Life Instrument to Measure Unmet Dental Care Needs in Adults With Inherited Bleeding Disorders

Haemophilia, EarlyView.
ABSTRACT Introduction Preventive dental care is vital for individuals with bleeding disorders to reduce the need for potentially invasive procedures. Although dental care is a mandated function of U.S. federally supported hemophilia treatment centers (HTCs), access to dental care is widely variable.
Miguel A. Escobar, Megan M. Ullman, Joanna Larson, Michael M. Chan, Marisela Trujillo   +4 more
wiley   +1 more source

Emicizumab in the treatment of acquired hemophilia A: A Two-Center experience

Annals of Hematology
Emicizumab is a FVIII mimetic antibody used in the treatment of inherited hemophilia A that could potentially be used in acquired hemophilia A (AHA) to achieve hemostasis and shorten hospital stay while reducing bypass therapies. We report on 12 cases of
Malcolm Su, Sean Yates, Melissa Sanchez, Yu-Min Shen   +3 more
doaj   +1 more source

Physical Activity and Sedentary Behaviour in Children With Haemophilia

Haemophilia, EarlyView.
ABSTRACT Introduction Physical activity (PA) is vital in child development, while inactivity remains a leading contributor to global mortality. Therapeutic advances have enabled greater PA in boys with haemophilia (BwH), yet robust UK data on objectively measured PA and sedentary behaviour (SB) across severities are limited.
Melanie Bladen, Lucy Alderson, Eleanor Main, Mario Cortina‐Borja   +3 more
wiley   +1 more source

Recurrent thrombosis in patients with antiphospholipid antibodies treated with vitamin K antagonists or rivaroxaban

Haematologica, 2018
Ida Martinelli, Maria Abbattista, Paolo Bucciarelli, Armando Tripodi, Andrea Artoni, Francesca Gianniello, Cristina Novembrino, Flora Peyvandi   +7 more
doaj   +1 more source

Accuracy of Factor VIII Assays for Measuring Damoctocog Alfa Pegol: A Comparative Analysis

Haemophilia, EarlyView.
ABSTRACT Introduction Accurate monitoring of treatment with modified factor VIII products remains challenging, due to known variability in assay performance across different laboratory methods and reagents. For the extended half‐life product Damoctocog alfa pegol discrepancies have been reported.
Judith C. A. Cluitmans, Piet Meijer, Sanna R. Rijpma, An K. Stroobants   +3 more
wiley   +1 more source